U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07113925) titled 'A Clinical Trial Evaluating TQB2101 in Subjects With Advanced Hematologic Malignancies' on July 31.
Brief Summary: TQB2101 for Injection is an Antibody-Drug Conjugate (ADC) targeting Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1).It consists of three main components: a ROR1 monoclonal antibody responsible for selectively recognizing the surface antigen of cancer cells, a small molecule toxin responsible for killing cancer cells, and a linker connecting the antibody and the small molecule toxin. It is intended for clinical use in the treatment of advanced malignant tumors, including advanced malignant hematological tumors.
S...